Jazz Pharmaceuticals plc
NASDAQ:JAZZ
129.85 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 4,068.95 | 3,834.204 | 3,659.374 | 3,094.238 | 2,363.567 |
| Cost of Revenue
| 445.713 | 435.577 | 540.517 | 440.76 | 148.917 |
| Gross Profit
| 3,623.237 | 3,398.627 | 3,118.857 | 2,653.478 | 2,214.65 |
| Gross Profit Ratio
| 0.89 | 0.886 | 0.852 | 0.858 | 0.937 |
| Reseach & Development Expenses
| 884 | 849.658 | 590.453 | 505.748 | 335.375 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1,385.294 | 1,343.105 | 1,416.967 | 1,451.683 | 854.233 |
| Other Expenses
| 637.313 | 627.284 | 1,176.965 | 525.769 | 646.969 |
| Operating Expenses
| 2,906.607 | 2,820.047 | 3,184.385 | 2,483.2 | 1,836.577 |
| Operating Income
| 716.63 | 578.58 | -65.528 | 170.278 | 378.073 |
| Operating Income Ratio
| 0.176 | 0.151 | -0.018 | 0.055 | 0.16 |
| Total Other Income Expenses Net
| -247.939 | -283.66 | -317.177 | -283.83 | -105.94 |
| Income Before Tax
| 468.691 | 294.92 | -382.705 | -113.552 | 272.133 |
| Income Before Tax Ratio
| 0.115 | 0.077 | -0.105 | -0.037 | 0.115 |
| Income Tax Expense
| -91.429 | -119.912 | -158.645 | 216.116 | 33.517 |
| Net Income
| 560.12 | 414.832 | -224.06 | -328.954 | 238.616 |
| Net Income Ratio
| 0.138 | 0.108 | -0.061 | -0.106 | 0.101 |
| EPS
| 9.06 | 6.55 | -3.58 | -5.51 | 4.28 |
| EPS Diluted
| 8.65 | 6.1 | -3.58 | -5.51 | 4.22 |
| EBITDA
| 1,521.711 | 1,449.422 | 1,468.615 | 1,027.746 | 1,043.715 |
| EBITDA Ratio
| 0.374 | 0.378 | 0.401 | 0.332 | 0.442 |